This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Top Analyst Reports for Broadcom, Berkshire Hathaway & Johnson & Johnson
by Mark Vickery
Broadcom gains on AI chip strength and VMware synergy, while JNJ and BRK.B ride momentum despite looming headwinds.
JNJNegative Net Change BRK.BNegative Net Change LVSNegative Net Change CLSPositive Net Change AVGOPositive Net Change PKENegative Net Change OKTAPositive Net Change ODCNegative Net Change
aerospace industrial-products insurance pharmaceuticals semiconductor
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed
by Zacks Equity Research
MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.
AZNNegative Net Change MRKPositive Net Change VRNAPositive Net Change
earnings pharmaceuticals
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NVSPositive Net Change LLYNegative Net Change BAYRYNegative Net Change INCYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk
by Zacks Equity Research
TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.
AZNNegative Net Change NVONegative Net Change NVDANegative Net Change TEMPositive Net Change
artificial-intelligence medical pharmaceuticals semiconductor
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
by Zacks Equity Research
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
RHHBYPositive Net Change BMYPositive Net Change EXELPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
by Zacks Equity Research
AZN's second-quarter revenues beat on strong drug sales across Oncology and CVRM despite in-line earnings.
SNYPositive Net Change AZNNegative Net Change MRKPositive Net Change AMGNPositive Net Change
pharmaceuticals
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
MRKPositive Net Change MRNAPositive Net Change EXASPositive Net Change BNTXPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
by Sundeep Ganoria
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
RHHBYPositive Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings-preview medical pharmaceuticals
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
AZNNegative Net Change BMYPositive Net Change MRKPositive Net Change MRNAPositive Net Change ABBVNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals vaccines
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
by Ekta Bagri
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
by Ahan Chakraborty
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
SNYPositive Net Change RHHBYPositive Net Change RLAYPositive Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
by Zacks Equity Research
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
REGNPositive Net Change VRTXNegative Net Change MRNAPositive Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
by Kinjel Shah
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
AZNNegative Net Change MRKPositive Net Change SMMTPositive Net Change VRNAPositive Net Change
cancer pharmaceuticals
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
RDYPositive Net Change MRKPositive Net Change AMGNPositive Net Change ALVOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well
by Zacks Equity Research
RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.
REGNPositive Net Change RHHBYPositive Net Change PRTAPositive Net Change
biotechnology earnings medical pharmaceuticals
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
by Sundeep Ganoria
LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.
AZNNegative Net Change PFEPositive Net Change MRKPositive Net Change LLYNegative Net Change
biotechs earnings medical pharmaceuticals
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
by Kinjel Shah
JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.
AZNNegative Net Change JNJNegative Net Change AMGNPositive Net Change ABBVNegative Net Change
pharmaceuticals
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group
by Zacks Equity Research
Rising cash flows put Catalyst, SunOpta, Gambling.com, and Orion Group in focus as strong picks amid earnings season.
STKLPositive Net Change ORNNegative Net Change CPRXPositive Net Change GAMBPositive Net Change
pharmaceuticals
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
BMYPositive Net Change JNJNegative Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
by Zacks Equity Research
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
ALKSPositive Net Change INCYPositive Net Change EXELPositive Net Change AKROPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?
by Zacks Equity Research
Merck's Keytruda drives nearly half of its pharma sales. Investors eye Q2 momentum amid existing competition.
AZNNegative Net Change RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change
pharmaceuticals
Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings
by Kinjel Shah
PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
pharmaceuticals
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
by Ahan Chakraborty
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
SDGRPositive Net Change RLAYPositive Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
by Sundeep Ganoria
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
NVONegative Net Change LLYNegative Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals